Betamimetics in fetal distress: randomised controlled trial

Area of Science:

• Obstetrics and Gynecology
• Neonatal Medicine
• Pharmacology

Background:

• Fetal distress is a critical condition requiring timely intervention.
• Hexoprenaline is a tocolytic agent with potential effects on fetal well-being.
• Evaluating its impact on neonatal outcomes is crucial for clinical practice.

Purpose of the Study:

• To determine if a single dose of Hexoprenaline improves neonatal outcomes in fetuses experiencing distress.
• To assess potential side effects and complications associated with Hexoprenaline administration.

Main Methods:

• A randomized controlled trial involving patients with fetal distress (gestational age ≥35 weeks) undergoing Cesarean section.
• Intravenous administration of 10 micrograms of Hexoprenaline to the study group.
• Comparison of neonatal outcomes including cord blood gas values, Apgar scores, resuscitation needs, and intensive care admissions between Hexoprenaline and control groups.

Main Results:

• No statistically significant differences were observed in primary outcome measures between the Hexoprenaline and control groups.
• A non-significant trend towards better cord blood pH (>7.2) and base excess (> -10) was noted in the Hexoprenaline group.
• A statistically significant improvement in fetal heart rate patterns was observed following Hexoprenaline administration.

Conclusions:

• Hexoprenaline administration showed a significant positive effect on fetal heart rate tracings in cases of fetal distress.
• Despite improvements in fetal heart rate, Hexoprenaline did not lead to statistically significant improvements in Apgar scores or cord blood gas values.
• Further research may be warranted to explore the nuanced effects of Hexoprenaline on neonatal outcomes.